Lassa Fever - Pipeline Insight, 2025: Advancing Antivirals and Vaccine Candidates Signal a Turning Point in Outbreak Management | DelveInsight

Lassa Fever, an acute viral hemorrhagic illness endemic to West Africa, continues to pose a significant public health threat with recurrent outbreaks and limited therapeutic options. Despite its high mortality in severe cases, treatment remains largely supportive, underscoring an urgent need for effective antivirals and preventive vaccines.

In 2025, the Lassa fever pipeline is evolving with over 3 candidates, including novel direct-acting antivirals, monoclonal antibodies, and advanced vaccine platforms under development. Key players such as Arisan Therapeutics and Imunon are actively progressing programs supported by global health partnerships and accelerated regulatory pathways.

DelveInsight's "Lassa Fever - Pipeline Insight, 2025" captures the current landscape, spotlighting efforts to bring first-in-class therapeutics and vaccines to populations in endemic regions. The report maps global R&D initiatives, platform technologies, and regulatory incentives that are driving faster development timelines.

With global attention on pandemic preparedness, the Lassa fever pipeline is poised to reshape outbreak containment, offering scalable and sustainable solutions for endemic countries and beyond.

Interested in learning more about the current treatment landscape and the key drivers shaping the Lassa Fever pipeline? Click here: https://www.delveinsight.com/report-store/lassa-fever-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Lassa Fever Pipeline Report
• DelveInsight's Lassa Fever pipeline analysis depicts a strong space with 3+ active players working to develop 3+ pipeline drugs for Lassa Fever treatment.
• The leading Lassa Fever companies include Arisan Therapeutics, Imunon, and others are evaluating their lead assets to improve the Lassa Fever treatment landscape.
• Key Lassa Fever pipeline therapies in various stages of development include ARN-75039, IMNN-102, and others.
• In March 2025, a first-in-humans Phase Ia clinical trial for MOPEVAC‐Lassa, a novel vaccine platform based on attenuated viral vectors, has been initiated by Institut Pasteur in Paris. Sponsored by France's government-backed France 2030 and led by Sylvain Baize, the trial aims to enroll 72 healthy volunteers to assess safety and immune responses. The initial dosing is planned for early 2026.
• In March 2025, the U.S. NIH/NIAID launched a Phase I trial for LASSARAB, a rabies‐vectored Lassa vaccine candidate, at the University of Maryland School of Medicine in Baltimore. Up to 55 healthy adults (aged 18-50) will receive two doses (28 days apart) to evaluate safety and immunogenicity. This marks a significant milestone as one of the first Lassa vaccine trials in the U.S.
• In January 2025, the West Africa Lassa Fever Consortium (WALC) unveiled a new standardized multi-country Phase II/III clinical trial framework. This innovative trial design aims to efficiently evaluate multiple therapeutic candidates in endemic West African regions, addressing logistical, regulatory, and strain diversity challenges.
• In August 2024, IAVI's Lassa fever vaccine candidate began a multisite Phase II trial across Ghana, Liberia, and Nigeria to evaluate safety, tolerability, and immunogenicity in adults (including persons with HIV), adolescents, and children ≥2 years old. Around 612 participants are enrolled, with follow-up planned through 2026.

Request a sample and discover the recent breakthroughs happening in the Lassa Fever pipeline landscape at https://www.delveinsight.com/report-store/lassa-fever-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Lassa Fever Overview
Lassa fever is an acute viral hemorrhagic illness caused by the Lassa virus, a member of the Arenaviridae family. Endemic to parts of West Africa-particularly Nigeria, Sierra Leone, Liberia, and Guinea-it is primarily transmitted to humans through exposure to food or household items contaminated with urine or feces of infected Mastomys rats. Human-to-human transmission can also occur via contact with the blood, tissue, or bodily fluids of infected individuals, especially in healthcare settings without proper infection control.

Most Lassa fever infections are mild or asymptomatic, but in severe cases, the disease can cause multi-organ dysfunction, hemorrhaging, respiratory distress, neurological complications, and death. The incubation period ranges from 6 to 21 days, and early symptoms often resemble other febrile illnesses, such as malaria or typhoid, making diagnosis challenging without laboratory testing.

There is currently no approved vaccine, and treatment primarily involves supportive care. The antiviral drug ribavirin has shown some effectiveness when administered early, but access remains limited. Due to its high mortality in severe cases, potential for outbreaks, and risk to healthcare workers, Lassa fever is recognized by the WHO as a priority pathogen for urgent research and development. Ongoing efforts are focused on developing effective vaccines, monoclonal antibodies, and antiviral therapies to improve disease management and outbreak preparedness.

Find out more about Lassa Fever medication at https://www.delveinsight.com/report-store/lassa-fever-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Lassa Fever Treatment Analysis: Drug Profile
ARN-75039: Arisan Therapeutics
ARN-75039 is a broad-spectrum entry inhibitor targeting arenaviruses, currently under development by Arisan Therapeutics for the treatment of Lassa fever. The compound has demonstrated promising antiviral activity in preclinical models, particularly in guinea pigs, where it was administered orally at a dose of 60 mg/kg once daily for 14 days, starting on day 2, 4, or 6 post-infection. These studies showed notable efficacy in reducing disease severity and improving survival. ARN-75039 is currently in Phase I clinical trials, marking an important step toward advancing therapeutic options for Lassa fever and related viral hemorrhagic fevers.

Learn more about the novel and emerging Lassa Fever pipeline therapies at https://www.delveinsight.com/report-store/lassa-fever-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Lassa Fever Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

By Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Scope of the Lassa Fever Pipeline Report
• Coverage: Global
• Key Lassa Fever Companies: Arisan Therapeutics, Imunon, and others.
• Key Lassa Fever Pipeline Therapies: ARN-75039, IMNN-102, and others.

Dive deep into rich insights for drugs used for Lassa Fever treatment, visit: https://www.delveinsight.com/report-store/lassa-fever-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Lassa Fever Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Lassa Fever Pipeline Therapeutics
6. Lassa Fever Pipeline: Late-Stage Products (Phase III)
7. Lassa Fever Pipeline: Mid-Stage Products (Phase II)
8. Lassa Fever Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.